Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Editorial: Cancer Plasticity and the Microenvironment: Implications for Immunity and Therapy Response.

Behren A, Thompson EW, Anderson RL, Ferrao PT.

Front Oncol. 2019 May 7;9:276. doi: 10.3389/fonc.2019.00276. eCollection 2019. No abstract available.

2.

Taking out the JNK: A window of opportunity to improve cancer therapy.

Ferrao PT.

Mol Cell Oncol. 2016 Jan 19;3(3):e1128515. doi: 10.1080/23723556.2015.1128515. eCollection 2016 May.

3.

Editorial: Cellular and Phenotypic Plasticity in Cancer.

Ferrao PT, Behren A, Anderson RL, Thompson EW.

Front Oncol. 2015 Aug 4;5:171. doi: 10.3389/fonc.2015.00171. eCollection 2015. No abstract available.

4.

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.

PMID:
26286024
5.

Phenotype switching in melanoma: implications for progression and therapy.

Li FZ, Dhillon AS, Anderson RL, McArthur G, Ferrao PT.

Front Oncol. 2015 Feb 13;5:31. doi: 10.3389/fonc.2015.00031. eCollection 2015. Review.

6.

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells.

Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA.

Oncogene. 2012 Mar 29;31(13):1661-72. doi: 10.1038/onc.2011.358. Epub 2011 Aug 15.

PMID:
21841818
7.

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.

Ferrao PT, Frost MJ, Siah SP, Ashman LK.

Blood. 2003 Dec 15;102(13):4499-503. Epub 2003 Jul 24.

PMID:
12881321

Supplemental Content

Loading ...
Support Center